<b>What Is the Drug of Choice for the Acute Termination of Paroxysmal Supraventricular Tachycardia:</b> Verapamil, Adenosine Triphosphate, or Adenosine?

Belhassen, Bernard; Viskin, Sami

doi:10.1111/j.1540-8159.1993.tb01044.x

Cited by 16 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, continuous perfusion of ATP in animal models where adenosine receptors were blocked showed both negative and positive chronotropic and inotropic effects of ATP, which were dose dependent [122,681]. Several reviews discuss the treatment of PSVT by ATP and adenosine [15,61,[682][683][684][685][686][687]. Adenosine was recommended for the diagnosis of wide complex tachycardia [688].…”

Section: Arrhythmiasmentioning

confidence: 99%

Cardiac purinergic signalling in health and disease

Burnstock

Pelleg

2014

Purinergic Signalling

118

View full text Add to dashboard Cite

This review is a historical account about purinergic signalling in the heart, for readers to see how ideas and understanding have changed as new experimental results were published. Initially, the focus is on the nervous control of the heart by ATP as a cotransmitter in sympathetic, parasympathetic, and sensory nerves, as well as in intracardiac neurons. Control of the heart by centers in the brain and vagal cardiovascular reflexes involving purines are also discussed. The actions of adenine nucleotides and nucleosides on cardiomyocytes, atrioventricular and sinoatrial nodes, cardiac fibroblasts, and coronary blood vessels are described. Cardiac release and degradation of ATP are also described. Finally, the involvement of purinergic signalling and its therapeutic potential in cardiac pathophysiology is reviewed, including acute and chronic heart failure, ischemia, infarction, arrhythmias, cardiomyopathy, syncope, hypertrophy, coronary artery disease, angina, diabetic cardiomyopathy, as well as heart transplantation and coronary bypass grafts.

show abstract

Section: Arrhythmiasmentioning

confidence: 99%

Cardiac purinergic signalling in health and disease

Burnstock

Pelleg

2014

Purinergic Signalling

118

View full text Add to dashboard Cite

show abstract

“…Adenosine and ATP are thought to have similar efficacy at terminating SVT. [ 48 ] Side-effects were noted to be minor and transient, but doses required were variable. This was accounted for by rapid clearance, variable rates of injection through different cannula sizes and the patient’s degree of intrinsic sympathetic tone.…”

Section: Electrophysiological Effects Of Adenosinementioning

confidence: 99%

Unmasking Adenosine: The Purinergic Signalling Molecule Critical to Arrhythmia Pathophysiology and Management

Matthews

Grace

2020

Arrhythm Electrophysiol Rev

View full text Add to dashboard Cite

Adenosine was identified in 1929 and immediately recognised as having a potential role in therapy for arrhythmia because of its negative chronotropic and dromotropic effects. Adenosine entered mainstream use in the 1980s as a highly effective agent for the termination of supraventricular tachycardia (SVT) involving the atrioventricular node, as well as for its ability to unmask the underlying rhythm in other SVTs. Adenosine has subsequently been found to have applications in interventional electrophysiology. While considered a safe agent because of its short half-life, adenosine may provoke arrhythmias in the form of AF, bradyarrhythmia and ventricular tachyarrhythmia. Adenosine is also associated with bronchospasm, although this may reflect irritant-induced dyspnoea rather than true obstruction. Adenosine is linked to numerous pathologies relevant to arrhythmia predisposition, including heart failure, obesity, ischaemia and the ageing process itself. This article examines 90 years of experience with adenosine in the light of new European Society of Cardiology guidelines for the management of SVT.

show abstract

“…[14] Adenozinin etki başlangıcı süre-si verapamilden daha kısa olup hipotansiyon ya da kalp yetmezliği olanlarda veya önce beta blokör denenmiş ama etki etmemiş hastalarda adenozinin daha faydalı ve daha az zararlı olduğu gösterilmiştir. [15] 2011 yılında European Journal of Emergency Medicine'de (EJEM) yayınlanan ve 8 çalışma-nın verilerini birleştiren bir meta-analize göre, Adenozinin PSVT'leri başarılı şekilde sinüs ritmine dönüştürme şansı verapamilden 1.27 kat (%95 GA 0.63-2.57) daha fazla olarak bulunmuştur, ancak aradaki fark istatistiksel olarak anlamlı değildir. [16] Minör istenmeyen olay insidansı adenozin ile daha fazlayken (Adenozin ile %16.7 ile %76 arasında, Verapamil ile %0 ile %9.9 arasında), hipotansiyon oranı adenozin ile (%0.6; %95 GA: %0.1-2.4) verapamilden (%3.7; %95 GA %1.9-6.9) daha düşüktür.…”

Section: Adenozinunclassified

New therapeutics and drugs available in Turkey

Akoğlu

2011

Tr J Emerg Med

View full text Add to dashboard Cite

What Is the Drug of Choice for the Acute Termination of Paroxysmal Supraventricular Tachycardia: Verapamil, Adenosine Triphosphate, or Adenosine?

Cited by 16 publications

References 26 publications

Cardiac purinergic signalling in health and disease

Cardiac purinergic signalling in health and disease

Unmasking Adenosine: The Purinergic Signalling Molecule Critical to Arrhythmia Pathophysiology and Management

New therapeutics and drugs available in Turkey

Contact Info

Product

Resources

About